Steven Reiter
Interventional Cardiology · Oklahoma City, OKNPI 1932103959
Payments from drug & device makers
Across 154 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$969
- Boehringer Ingelheim$261
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$229
- AstraZeneca$181
- Novartis$155
- Merck$120
- plus $628 from 16 others
What the payments were for
- Food & beverage$2,545100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 60 | $969 |
| Boehringer Ingelheim | 15 | $261 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $229 |
| AstraZeneca | 11 | $181 |
| Novartis | 8 | $155 |
| Merck | 8 | $120 |
| E.r. Squibb & Sons, L.L.C. | 7 | $118 |
| Kowa Pharmaceuticals America, Inc. | 7 | $110 |
| Lundbeck LLC | 4 | $70 |
| Novo Nordisk | 3 | $60 |
| Actelion Pharmaceuticals US, Inc. | 3 | $38 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $37 |
| Abbott | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Amgen | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Bayer | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$2,545 in reported general payments places this provider in the 20th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 600 | $575,332 |
| JardianceEmpagliflozin | 346 | $417,516 |
| EliquisApixaban | 427 | $416,761 |
| OzempicSemaglutide | 99 | $129,785 |
| FarxigaDapagliflozin Propanediol | 101 | $106,016 |
| Repatha SureclickEvolocumab | 126 | $86,641 |
| EntrestoSacubitril/Valsartan | 67 | $75,948 |
| Praluent PenAlirocumab | 58 | $27,318 |
| JanuviaSitagliptin Phosphate | 22 | $26,493 |
| VascepaIcosapent Ethyl | 32 | $19,974 |
| MultaqDronedarone Hcl | 18 | $19,015 |
| LivaloPitavastatin Calcium | 24 | $17,332 |
| Atorvastatin Calcium | 1,020 | $16,710 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,584 |
| Ezetimibe | 433 | $14,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $969 | $575,332600 claims |
| Boehringer IngelheimJardiance | $261 | $417,516346 claims |
| PfizerEliquis | $17 | $416,761427 claims |
| Novo NordiskOzempic | $60 | $129,78599 claims |
| AstraZenecaFarxiga, Brilinta | $181 | $118,401114 claims |
| NovartisEntresto | $155 | $75,94867 claims |
| MerckJanuvia | $120 | $26,49322 claims |
| Sanofi-aventis U.S. LLCMultaq | $13 | $19,01518 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $110 | $17,33224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- Naeem TahirkheliOklahoma City$8.6M
- Mohammad GhaniOklahoma City$1.8M
- George ChrysantOklahoma City$873K
- Usman BaberOklahoma City$736K
- Jeffrey SparlingOklahoma City$381K
- Thomas McGarryOklahoma City$153K
- Faisal LatifOklahoma City$129K
- Branislav SchifferdeckerOklahoma City$121K
- Mazen Abu-FadelOklahoma City$98K
- Dwayne SchmidtOklahoma City$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.